星空体育官方入口网站网址大全-登录入口官网

#HSCT#

28篇内容 | 1190人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1578440, encodeId=bf3415e844088, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=JNNP:既往疾病改良治疗对AHSCT治疗MS患者安全性和疗效的影响, objectType=article, longId=729933, objectId=fa88e29933d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa88e29933d2, replyNumber=0, likeNumber=125, createdTime=2022-06-20, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa88e29933d2, moduleTitle=JNNP:既往疾病改良治疗对AHSCT治疗MS患者安全性和疗效的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fa88e29933d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578439, encodeId=b00c15e8439a9, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=allo-HSCT后供者细胞上的抗原表达缺失或下调了？, objectType=article, longId=727041, objectId=68b2e270414b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68b2e270414b, replyNumber=0, likeNumber=64, createdTime=2022-05-17, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68b2e270414b, moduleTitle=allo-HSCT后供者细胞上的抗原表达缺失或下调了？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=68b2e270414b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578438, encodeId=80fc15e843811, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=腺病毒感染与移植：造血干细胞移植(HSCT)和实体器官移植(SOT)人群感染情况, objectType=article, longId=221732, objectId=df63221e32a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df63221e32a5, replyNumber=0, likeNumber=71, createdTime=2021-12-10, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df63221e32a5, moduleTitle=腺病毒感染与移植：造血干细胞移植(HSCT)和实体器官移植(SOT)人群感染情况, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=df63221e32a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578437, encodeId=ad4015e843735, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=J Clin Oncol：5-aza+HSCT可显著提高MDS老年患者的生存率, objectType=article, longId=214570, objectId=899e2145e0f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=899e2145e0f2, replyNumber=0, likeNumber=66, createdTime=2021-07-23, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=899e2145e0f2, moduleTitle=J Clin Oncol：5-aza+HSCT可显著提高MDS老年患者的生存率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=899e2145e0f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578436, encodeId=874215e8436ac, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著, objectType=article, longId=206905, objectId=e68520690580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e68520690580, replyNumber=0, likeNumber=56, createdTime=2021-02-09, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e68520690580, moduleTitle=Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e68520690580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578435, encodeId=3d2215e843522, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=J Clin Oncol：强化调理方案不能改善高危型AML/MDS老年患者allo-HSCT后的预后, objectType=article, longId=205037, objectId=941420503ec4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=941420503ec4, replyNumber=0, likeNumber=68, createdTime=2021-01-01, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=941420503ec4, moduleTitle=J Clin Oncol：强化调理方案不能改善高危型AML/MDS老年患者allo-HSCT后的预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=941420503ec4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578434, encodeId=61a415e843494, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=J Clin Oncol：儿童ALL进行allo-HSCT前的最适清髓方案, objectType=article, longId=204947, objectId=fb6b20494eeb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb6b20494eeb, replyNumber=0, likeNumber=66, createdTime=2020-12-30, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb6b20494eeb, moduleTitle=J Clin Oncol：儿童ALL进行allo-HSCT前的最适清髓方案, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fb6b20494eeb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578433, encodeId=c50715e8433a3, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=Blood：高风险费城染色体阴性ALL成年患者要不要进行allo-HSCT？, objectType=article, longId=203575, objectId=a1f82035e5b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1f82035e5b3, replyNumber=0, likeNumber=60, createdTime=2020-11-22, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1f82035e5b3, moduleTitle=Blood：高风险费城染色体阴性ALL成年患者要不要进行allo-HSCT？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a1f82035e5b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578432, encodeId=827215e843208, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=JCO：rhG-CSF联合小剂量地西他滨可降低HR-AML患者allo-HSCT后的复发率, objectType=article, longId=203319, objectId=209120331967, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=209120331967, replyNumber=0, likeNumber=87, createdTime=2020-11-14, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=209120331967, moduleTitle=JCO：rhG-CSF联合小剂量地西他滨可降低HR-AML患者allo-HSCT后的复发率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=209120331967)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578431, encodeId=755715e8431b9, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=Blood：采用HSCT治疗的恶性血液病患儿的长期预后, objectType=article, longId=191552, objectId=8f6319155265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f6319155265, replyNumber=0, likeNumber=60, createdTime=2020-04-07, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f6319155265, moduleTitle=Blood：采用HSCT治疗的恶性血液病患儿的长期预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8f6319155265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578430, encodeId=aa5f15e8430b8, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=Blood：allo-HSCT后的长期存活者及其供体的克隆造血分析, objectType=article, longId=190570, objectId=10061905e0ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10061905e0ea, replyNumber=0, likeNumber=60, createdTime=2020-03-23, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10061905e0ea, moduleTitle=Blood：allo-HSCT后的长期存活者及其供体的克隆造血分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=10061905e0ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578429, encodeId=b73415e842961, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=Blood：eculizumab阻断补体激活明显改善高TA-TMA风险患者HSCT后的存活率, objectType=article, longId=186299, objectId=325e1862994a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=325e1862994a, replyNumber=0, likeNumber=56, createdTime=2020-01-16, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=325e1862994a, moduleTitle=Blood：eculizumab阻断补体激活明显改善高TA-TMA风险患者HSCT后的存活率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=325e1862994a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578428, encodeId=e9e215e8428d6, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=Blood：消化道抗原提呈细胞在alloHSCT后GVHD中的重要作用, objectType=article, longId=182474, objectId=0df41824e457, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0df41824e457, replyNumber=0, likeNumber=66, createdTime=2019-11-07, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0df41824e457, moduleTitle=Blood：消化道抗原提呈细胞在alloHSCT后GVHD中的重要作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0df41824e457)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578427, encodeId=19ae15e8427f6, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=Blood：αβT/B细胞敲除后进行HLA相合性造血干细胞移植（αβhaplo-HSCT）可有效治疗急性白血病, objectType=article, longId=151767, objectId=d624151e67f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d624151e67f4, replyNumber=0, likeNumber=50, createdTime=2018-10-25, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d624151e67f4, moduleTitle=Blood：αβT/B细胞敲除后进行HLA相合性造血干细胞移植（αβhaplo-HSCT）可有效治疗急性白血病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d624151e67f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578426, encodeId=25f615e842619, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=Brit J Haematol：R/R-AML患者 HSCT前用高剂量美法仑更有利？, objectType=article, longId=144794, objectId=13f5144e942c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13f5144e942c, replyNumber=0, likeNumber=60, createdTime=2018-07-21, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13f5144e942c, moduleTitle=Brit J Haematol：R/R-AML患者 HSCT前用高剂量美法仑更有利？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=13f5144e942c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578425, encodeId=e56915e842589, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=Blood：产生丁酸盐的肠道菌群可降低allo-HSCT后的患者发生呼吸道病毒感染的风险, objectType=article, longId=136012, objectId=da8313601242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da8313601242, replyNumber=0, likeNumber=71, createdTime=2018-04-22, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da8313601242, moduleTitle=Blood：产生丁酸盐的肠道菌群可降低allo-HSCT后的患者发生呼吸道病毒感染的风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=da8313601242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578424, encodeId=bfc915e8424eb, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=Expert Rev Vaccines：植入前革兰氏阴性菌血症对自、异体HSCT后死亡率风险有何影响？, objectType=article, longId=124965, objectId=9bc112496558, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bc112496558, replyNumber=0, likeNumber=43, createdTime=2017-12-30, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bc112496558, moduleTitle=Expert Rev Vaccines：植入前革兰氏阴性菌血症对自、异体HSCT后死亡率风险有何影响？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9bc112496558)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578423, encodeId=284c15e8423e2, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=【2017 ASH】复发难治性慢性淋巴细胞白血病17p缺失突变患者治疗方案的选择——伊布替尼vs HSCT, objectType=article, longId=123311, objectId=ff8a12331154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff8a12331154, replyNumber=0, likeNumber=49, createdTime=2017-12-15, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff8a12331154, moduleTitle=【2017 ASH】复发难治性慢性淋巴细胞白血病17p缺失突变患者治疗方案的选择——伊布替尼vs HSCT, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ff8a12331154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578422, encodeId=07b115e84228a, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=Blood：半相合HSCT后应用环磷酰胺管理对NK细胞的影响。, objectType=article, longId=115446, objectId=bc9311544609, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc9311544609, replyNumber=0, likeNumber=55, createdTime=2017-10-10, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc9311544609, moduleTitle=Blood：半相合HSCT后应用环磷酰胺管理对NK细胞的影响。, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bc9311544609)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1578421, encodeId=17ca15e8421e9, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, objectTitle=Blood：在同种异体HSCT后，至少需要20%供体髓细胞嵌合才可逆转镰刀型细胞贫血。, objectType=article, longId=112514, objectId=16c211251429, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16c211251429, replyNumber=0, likeNumber=76, createdTime=2017-09-12, rootId=0, userName=ms691033630344116, userId=0df016405434, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16c211251429, moduleTitle=Blood：在同种异体HSCT后，至少需要20%供体髓细胞嵌合才可逆转镰刀型细胞贫血。, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=16c211251429)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HSCT

2020-05-29

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

JNNP:既往疾病改良治疗对AHSCT治疗MS患者安全性和疗效的影响

2022-06-20

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

allo-HSCT后供者细胞上的抗原表达缺失或下调了？

2022-05-17

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

腺病毒感染与移植：造血干细胞移植(HSCT)和实体器官移植(SOT)人群感染情况

2021-12-10

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

J Clin Oncol：5-aza+HSCT可显著提高MDS老年患者的生存率

2021-07-23

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著

2021-02-09

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

J Clin Oncol：强化调理方案不能改善高危型AML/MDS老年患者allo-HSCT后的预后

2021-01-01

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

J Clin Oncol：儿童ALL进行allo-HSCT前的最适清髓方案

2020-12-30

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

Blood：高风险费城染色体阴性ALL成年患者要不要进行allo-HSCT？

2020-11-22

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

JCO：rhG-CSF联合小剂量地西他滨可降低HR-AML患者allo-HSCT后的复发率

2020-11-14

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

Blood：采用HSCT治疗的恶性血液病患儿的长期预后

2020-04-07

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

Blood：allo-HSCT后的长期存活者及其供体的克隆造血分析

2020-03-23

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

Blood：eculizumab阻断补体激活明显改善高TA-TMA风险患者HSCT后的存活率

2020-01-16

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

Blood：消化道抗原提呈细胞在alloHSCT后GVHD中的重要作用

2019-11-07

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

Blood：αβT/B细胞敲除后进行HLA相合性造血干细胞移植（αβhaplo-HSCT）可有效治疗急性白血病

2018-10-25

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

Brit J Haematol：R/R-AML患者 HSCT前用高剂量美法仑更有利？

2018-07-21

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

Blood：产生丁酸盐的肠道菌群可降低allo-HSCT后的患者发生呼吸道病毒感染的风险

2018-04-22

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

Expert Rev Vaccines：植入前革兰氏阴性菌血症对自、异体HSCT后死亡率风险有何影响？

2017-12-30

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

【2017 ASH】复发难治性慢性淋巴细胞白血病17p缺失突变患者治疗方案的选择——伊布替尼vs HSCT

2017-12-15

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

Blood：半相合HSCT后应用环磷酰胺管理对NK细胞的影响。

2017-10-10

ms691033630344116 (审核中...)

前往app查看评论内容

#HSCT#

Blood：在同种异体HSCT后，至少需要20%供体髓细胞嵌合才可逆转镰刀型细胞贫血。

2017-09-12

科室
- - 订阅+
  - 更多科室
工具
服务